Trial Profile
A Randomized, Open-label and Parallel Phase I Study to Compare Pharmacokinetics, Pharmacodynamics and Safety of Goserelin Acetate Sustained-Release Microspheres for Injection (LY01005) and ZOLADEX® Following Multiple Administration in Patients With Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 May 2023
Price :
$35
*
At a glance
- Drugs Goserelin (Primary) ; Bicalutamide; Goserelin
- Indications Prostate cancer
- Focus Pharmacokinetics
- Sponsors Luye Pharma Group
- 15 May 2023 Status changed from active, no longer recruiting to completed.
- 19 Nov 2021 Status changed from not yet recruiting to active, no longer recruiting.
- 06 Oct 2016 New trial record